On September 22, 2021 Legend Biotech Corporation (NASDAQ: LEGN), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that it will host its first Research & Development Day on Monday, October 18, commencing at 10:00 a.m. (Eastern Time), at Andaz 5th Avenue in New York (Press release, Legend Biotech, SEP 22, 2021, View Source [SID1234590142]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The meeting will feature updates on the company’s advancing pipeline of hematological and oncological indications and expanding cell therapy capabilities, including its B cell maturation antigen (BCMA) clinical development program. Presentations will be delivered by Legend’s senior leadership team:
Ying Huang, PhD, Chief Executive Officer and Chief Financial Officer
Frank Fan, MD, PhD, Chief Scientific Officer
Steve Gavel, Vice President, US & Europe Commercial
Lida Pacaud, MD, Vice President, Clinical Development
A live webcast and presentation will be available to investors and other interested parties on the Legend Biotech website under "Events and Presentations". A recording of the webcast can be viewed as early as 24 hours after the event and will be archived for six months.
To register for the event, please visit this link.